Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials.
Kawahara T, Iwamoto T, Takashima I, Hanazawa R, Uemura K, Uemura Y, Mukai H, Kikawa Y, Taira N. Kawahara T, et al. Among authors: kikawa y. Support Care Cancer. 2022 Oct;30(10):8367-8375. doi: 10.1007/s00520-022-07283-0. Epub 2022 Jul 20. Support Care Cancer. 2022. PMID: 35857127 Free PMC article.
Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan.
Iwamoto T, Taira N, Fujisawa T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Shien T, Takao S, Sato M, Goto Y, Yoshida T, Takahashi M, Aihara T, Mukai H. Iwamoto T, et al. Among authors: kikawa y. Acta Med Okayama. 2018 Aug;72(4):369-374. doi: 10.18926/AMO/56172. Acta Med Okayama. 2018. PMID: 30140084 Free article.
Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.
Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y. Niikura N, et al. Among authors: kikawa y. Oncologist. 2020 Feb;25(2):e223-e230. doi: 10.1634/theoncologist.2019-0382. Epub 2019 Oct 8. Oncologist. 2020. PMID: 32043762 Free PMC article. Clinical Trial.
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
Iwamoto T, Fujisawa T, Shien T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N. Iwamoto T, et al. Among authors: kikawa y. Breast Cancer. 2020 Sep;27(5):973-981. doi: 10.1007/s12282-020-01095-y. Epub 2020 May 11. Breast Cancer. 2020. PMID: 32394413 Free article.
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Taira N, Takashima T, Kashiwabara K, Aihara T, Mukai H. Tsurutani J, et al. Among authors: kikawa y. Breast. 2021 Feb;55:63-68. doi: 10.1016/j.breast.2020.12.002. Epub 2020 Dec 9. Breast. 2021. PMID: 33341707 Free PMC article. Clinical Trial.
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
Nakatsukasa K, Niikura N, Kashiwabara K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Yamashita T, Umeda M, Mukai H, Ota Y. Nakatsukasa K, et al. Among authors: kikawa y. BMC Cancer. 2021 Jan 7;21(1):34. doi: 10.1186/s12885-020-07746-9. BMC Cancer. 2021. PMID: 33413212 Free PMC article. Clinical Trial.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M. Masuda N, et al. Among authors: kikawa y. Breast Cancer Res Treat. 2021 Jul;188(1):117-131. doi: 10.1007/s10549-021-06184-w. Epub 2021 Mar 25. Breast Cancer Res Treat. 2021. PMID: 33763789 Free PMC article. Clinical Trial.
Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC).
Umeda M, Ota Y, Kashiwabara K, Hayashi N, Naito M, Yamashita T, Mukai H, Nakatsukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Niikura N. Umeda M, et al. Among authors: kikawa y. Ann Transl Med. 2021 Apr;9(7):535. doi: 10.21037/atm-20-6488. Ann Transl Med. 2021. PMID: 33987233 Free PMC article.
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Taira N, et al. Among authors: kikawa y. Breast Cancer. 2022 Jan;29(1):131-143. doi: 10.1007/s12282-021-01290-5. Epub 2021 Sep 7. Breast Cancer. 2022. PMID: 34491513 Free PMC article. Clinical Trial.
112 results